• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

    5/1/25 5:00:00 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRO alert in real time by email

    FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph.

    Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company's consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.

    About Channel

    Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media.

    Channel Media and Investor Inquires:

    For Investor Inquiries:

    Mike Moyer

    Managing Director, LifeSci Advisors, LLC

    [email protected]



    Primary Logo

    Get the next $CHRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CHRO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

      ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for high un

      7/10/25 8:00:00 AM ET
      $CHRO
      $PTHS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

      FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and in

      6/27/25 9:15:00 AM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Malamut Richard bought $9,825 worth of shares (10,400 units at $0.94) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:56:55 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $5,044 worth of shares (5,200 units at $0.97) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:55:23 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $10,955 worth of shares (12,000 units at $0.91) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/12/24 5:35:41 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Baxter Richard B

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/7/25 9:47:34 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Greenleaf Peter

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/7/25 9:46:35 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pauls Matthew

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/7/25 9:45:34 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    SEC Filings

    See more
    • SEC Form D filed by Channel Therapeutics Corporation

      D - Pelthos Therapeutics Inc. (0001919246) (Filer)

      7/10/25 4:15:20 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Channel Therapeutics Corporation

      SCHEDULE 13G - Pelthos Therapeutics Inc. (0001919246) (Subject)

      7/8/25 4:05:35 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Channel Therapeutics Corporation

      SCHEDULE 13D/A - Pelthos Therapeutics Inc. (0001919246) (Subject)

      7/3/25 9:07:22 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Chromocell Therapeutics Corporation

      SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

      11/13/24 4:05:24 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/4/24 4:07:02 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/1/24 5:19:37 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations